Compare WRN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRN | NBTX |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.2M | 2.3B |
| IPO Year | 2006 | 2018 |
| Metric | WRN | NBTX |
|---|---|---|
| Price | $2.37 | $39.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.58 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 907.1K | 150.4K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $8.03 |
| 52 Week High | $4.26 | $57.14 |
| Indicator | WRN | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 47.06 |
| Support Level | $2.28 | $36.98 |
| Resistance Level | $2.54 | $41.06 |
| Average True Range (ATR) | 0.09 | 2.80 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 13.22 | 22.76 |
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.